advertisement

---

Verboven Y 4

Showing records 1 to 4 | Display all abstracts from Verboven Y

47838 Visual field evolution in glaucoma patients presenting with different disease stages: Results from an observational study
Gerlier L; Shlaen R; Wolfram C; Lamotte M; Verboven Y
Value in Health 2011; 14: A502-A503

---

47832 Economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad(registered trademark) instead of benzalkonium chloride in Germany
Gerlier L; Lamotte M; Lorenz K; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A503

---

47833 Longer term patient benefits of polyquad(registered trademark) preservative instead of benzalkonium chloride in prostaglandin eye drops: A microsimulation model in ocular hypertension and open-angle glaucoma
Gerlier L; Lamotte M; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A502

---

47836 Glaucoma management cost as a function of disease stage and treatment changes
Gerlier L; Shlaen R; Lorenz K; Lamotte M; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A505

---